Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.41 |
| ▸ | CCR5 | P51681 | 2/20 | 0.41 |
| ▸ | CCR8 | P51685 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.41 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RET | P07949 | 5/20 | 0.39 |
| ▸ | TP53 | P04637 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29911872 | 0.98 | ADORA1 (0.41) | ADORA1KDM4ELMNACCR1CCR5 | |
| SCHEMBL25818831 | 0.80 | KDM4E (0.43) | ADORA1KDM4ELMNACCR1CCR5 | |
| Hydrochloric Acid SCHEMBL28976188 | 0.79 | KDM4E (0.42) | ADORA1KDM4ELMNACCR1CCR5 | |
| SCHEMBL28052586 | 0.76 | ADORA2A (0.43) | ADORA1 | |
| SCHEMBL29911966 | 0.75 | ADORA1 (0.41) | ADORA1KDM4ELMNAPOLBNPC1 | |
| SCHEMBL29068847 | 0.73 | KDM4E (0.52) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL29911884 | 0.71 | DYRK1A (0.54) | ADORA1KDM4ELMNACCR1CCR5 | |
| SCHEMBL12777958 | 0.71 | DYRK1A (0.54) | ADORA1KDM4ELMNACCR1CCR5 | |
| SCHEMBL310349 | 0.71 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL30791149 | 0.71 | KDM4E (0.54) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4212523-A1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| US-11530194-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210214342-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | RIGEL PHARMACEUTICALS, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| US-10947216-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10414753-B2 | Amide compounds and method for making and using | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-17 | — | — | US | disclosed |
| WO-2018081294-A1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20180111917-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | MIDCAP FINANCIAL TRUST | 2018-04-26 | — | — | US | disclosed |
| US-20180111917-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | MIDCAP FINANCIAL TRUST | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947216-B2 | Amide compounds and method for making and using | IRAK1, IRAK2, IRAK3 | ADORA1 1327/4885KDM4E 929/4885LMNA 2345/4885 |
| US-20180111917-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | ADORA1 1327/4885KDM4E 929/4885LMNA 2345/4885 |
| US-10414753-B2 | Amide compounds and method for making and using | IRAK1, IRAK2, IRAK3 | ADORA1 1327/4885KDM4E 929/4885LMNA 2345/4885 |
| US-11530194-B2 | Amide compounds and method for making and using | IRAK1, IRAK2, IRAK3 | ADORA1 1327/4885KDM4E 929/4885LMNA 2345/4885 |
| US-20210214342-A1 | AMIDE COMPOUNDS AND METHOD FOR MAKING AND USING | IRAK1, IRAK2, IRAK3 | ADORA1 1327/4885KDM4E 929/4885LMNA 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.